Preview

Safety and Risk of Pharmacotherapy

Advanced search

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease

https://doi.org/10.30895/2312-7821-2023-11-4-473-474

Abstract

This article is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Review previously published in the Cochrane Database of Systematic Reviews. Original publication: Schmidt AF, Carter J-PL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas J. PCSK9 monoclonal antibodies for the primary and secon dary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2020, Issue 10. Art. No.: CD011748. https://doi.org/10.1002/14651858.CD011748.pub3

About the Author

article Editorial

Russian Federation


Review

For citations:


PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease. Safety and Risk of Pharmacotherapy. 2023;11(4):473-474. (In Russ.) https://doi.org/10.30895/2312-7821-2023-11-4-473-474

Views: 686


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)